Literature DB >> 32248359

ATP7B variant penetrance explains differences between genetic and clinical prevalence estimates for Wilson disease.

Daniel F Wallace1, James S Dooley2.   

Abstract

Wilson disease (WD) is a genetic disorder of copper metabolism caused by variants in the copper transporting P-type ATPase gene ATP7B. Estimates for WD population prevalence vary with 1 in 30,000 generally quoted. However, some genetic studies have reported much higher prevalence rates. The aim of this study was to estimate the population prevalence of WD and the pathogenicity/penetrance of WD variants by determining the frequency of ATP7B variants in a genomic sequence database. A catalogue of WD-associated ATP7B variants was constructed, and then, frequency information for these was extracted from the gnomAD data set. Pathogenicity of variants was assessed by (a) comparing gnomAD allele frequencies against the number of reports for variants in the WD literature and (b) using variant effect prediction algorithms. 231 WD-associated ATP7B variants were identified in the gnomAD data set, giving an initial estimated population prevalence of around 1 in 2400. After exclusion of WD-associated ATP7B variants with predicted low penetrance, the revised estimate showed a prevalence of around 1 in 20,000, with higher rates in the Asian and Ashkenazi Jewish populations. Reanalysis of other recent genetic studies using our penetrance criteria also predicted lower population prevalences for WD in the UK and France than had been reported. Our results suggest that differences in variant penetrance can explain the discrepancy between reported epidemiological and genetic prevalences of WD. They also highlight the challenge in defining penetrance when assigning causality to some ATP7B variants.

Entities:  

Year:  2020        PMID: 32248359     DOI: 10.1007/s00439-020-02161-3

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  5 in total

1.  Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity.

Authors:  Luis García-Villarreal; Andrea Hernández-Ortega; Ana Sánchez-Monteagudo; Luis Peña-Quintana; Teresa Ramírez-Lorenzo; Marta Riaño; Raquel Moreno-Pérez; Alberto Monescillo; Daniel González-Santana; Ildefonso Quiñones; Almudena Sánchez-Villegas; Vicente Olmo-Quintana; Paloma Garay-Sánchez; Carmen Espinós; Jesús M González; Antonio Tugores
Journal:  J Gastroenterol       Date:  2020-11-07       Impact factor: 7.527

2.  Estimating the clinical prevalence of Wilson's disease in the UK.

Authors:  Pramudi Wijayasiri; Jatinder Hayre; Edward S Nicholson; Philip Kaye; Emilie A Wilkes; Jonathan Evans; Guruprasad P Aithal; Gabriela Jones; Fiona Pearce; Aloysious D Aravinthan
Journal:  JHEP Rep       Date:  2021-07-07

3.  Clinical and genetic characterization of a large cohort of patients with Wilson's disease in China.

Authors:  Shijie Zhang; Wenming Yang; Xiang Li; Pei Pei; Ting Dong; Yue Yang; Jing Zhang
Journal:  Transl Neurodegener       Date:  2022-02-28       Impact factor: 8.014

Review 4.  The Role of Zinc in the Treatment of Wilson's Disease.

Authors:  Abolfazl Avan; Anna Członkowska; Susan Gaskin; Alberto Granzotto; Stefano L Sensi; Tjaard U Hoogenraad
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

5.  Pathogenic gene variation spectrum and carrier screening for Wilson's disease in Qingdao area.

Authors:  Lingyan Qiao; Juan Ge; Cheng Li; Yusheng Liu; Conghui Hu; Sicui Hu; Wenjie Li; Tang Li
Journal:  Mol Genet Genomic Med       Date:  2021-07-09       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.